Valuation: Royalty Pharma plc

Market Cap 25.79B 22.6B 20.89B 19.22B 36.26B 2,487B 36.84B 250B 97.94B 1,217B 96.84B 94.73B 4,192B P/E 2026 *
22x
P/E 2027 * 15.3x
Enterprise Value 34.94B 30.63B 28.31B 26.04B 49.13B 3,370B 49.92B 339B 133B 1,649B 131B 128B 5,680B EV / Sales 2026 *
10.1x
EV / Sales 2027 * 9.48x
Free-Float
71.97%
Yield 2026 *
1.72%
Yield 2027 * 1.81%
1 day-0.12%
1 week+2.85%
Current month+3.55%
1 month+8.38%
3 months+17.77%
6 months+48.53%
Current year+50.26%
1 week 54.95
Extreme 54.95
59.44
1 month 52.89
Extreme 52.89
59.44
Current year 38.29
Extreme 38.29
59.44
1 year 34.08
Extreme 34.0805
59.44
3 years 24.05
Extreme 24.05
59.44
5 years 24.05
Extreme 24.05
59.44
10 years 24.05
Extreme 24.05
59.44
Manager TitleAgeSince
Chief Executive Officer 62 1995-12-31
Director of Finance/CFO 44 2009-12-31
Chief Tech/Sci/R&D Officer - 2023-09-20
Director TitleAgeSince
Chairman 62 2020-03-31
Director/Board Member 68 2020-02-10
Director/Board Member 63 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Executive/Senior Manager

-9,099 0.0021%
6/30/26 Free

Director

689 0.0002%
6/30/26 Sell

Executive/Senior Manager

-130,000 0.0293%
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%+2.85%+62.86%+86.27% 25.79B
-1.03%-1.11%+53.35%+151.99% 1,051B
-0.90%-2.65%+52.67%+49.03% 609B
-0.31%+2.29%+37.23%+78.40% 450B
-0.75%+0.30%+29.77%+21.15% 330B
-1.52%-1.19%+34.46%+35.35% 284B
-1.70%-1.82%+20.99%+15.74% 263B
-0.58%+1.11%-20.18%-40.59% 223B
+0.09%+1.69%+23.89%+57.16% 198B
-0.19%+1.90%+23.66%+67.50% 167B
Average -0.64%+0.79%+31.87%+52.20% 360.09B
Weighted average by Cap. -0.76%+0.05%+37.72%+72.70%

Financials

2026 *2027 *
Net sales 3.47B 3.04B 2.81B 2.59B 4.88B 335B 4.96B 33.61B 13.18B 164B 13.03B 12.74B 564B 3.71B 3.25B 3B 2.76B 5.21B 357B 5.29B 35.9B 14.07B 175B 13.92B 13.61B 602B
Net income 1.65B 1.45B 1.34B 1.23B 2.33B 159B 2.36B 16.02B 6.28B 78.03B 6.21B 6.07B 269B 2.24B 1.96B 1.81B 1.67B 3.14B 216B 3.2B 21.67B 8.49B 106B 8.4B 8.22B 364B
Net Debt 9.15B 8.02B 7.42B 6.82B 12.87B 883B 13.08B 88.68B 34.76B 432B 34.37B 33.62B 1,488B 9.33B 8.17B 7.56B 6.95B 13.11B 899B 13.32B 90.34B 35.41B 440B 35.02B 34.25B 1,516B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Employees
100
Date Price Change Volume
26-07-20 US$58.09 -0.15% 1,051,547
26-07-17 US$58.18 -0.60% 2,540,469
26-07-16 US$58.53 +3.94% 3,591,515
26-07-15 US$56.31 +1.15% 2,749,371
26-07-14 US$55.67 -1.38% 2,231,398
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
58.18USD
Average target price
59.89USD
Spread / Average Target
+2.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RPRX Stock